Overview
Marfan’s syndrome is a systemic disorder of connective tissue caused by mutations in the extracellular matrix protein fibrillin 1. Cardinal manifestations include proximal aortic aneurysm, dislocation of the ocular lens, and long-bone overgrowth. Important advances have been made in the diagnosis and medical and surgical care of affected individuals, yet substantial morbidity and premature mortality remain associated with this disorder. Progress has been made with genetically defined mouse models to elucidate the pathogenetic sequence that is initiated by fibrillin-1 deficiency. The new understanding is that many aspects of the disease are caused by altered regulation of transforming growth factor β (TGFβ), a family of cytokines that affect cellular performance, highlighting the potential therapeutic application of TGF β antagonists. Insights derived from studying this mendelian disorder are anticipated to have relevance for more common and non-syndromic presentations of selected aspects of the Marfan phenotype.
Marfan’s syndrome is a systemic disorder of connective tissue, first described more than 100 years ago by a Parisian professor of paediatrics, Antoine-Bernard Marfan, who reported the association of long slender digits and other skeletal abnormalities in a 5-year-old girl, Gabrielle.1 Today, the disorder that bears his name has benefited from decades of clinical and molecular investigation. This review will highlight the clinical manifestations, molecular pathogenesis, standard treatment, and emerging therapeutic options for this multisystem disorder.